Champions Oncology Files 2024 10-K

TL;DR

Champions Oncology filed its 2024 10-K. All systems go.

AI Summary

Champions Oncology, Inc. filed its 10-K for the fiscal year ending April 30, 2024. The company, previously known as Champions Biotechnology, Inc., is involved in biological products. Its principal executive offices are located at 855 N. Wolfe Street, Suite 619, Baltimore, MD 21205.

Why It Matters

This filing provides a comprehensive overview of Champions Oncology's financial health and business operations for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The provided text is a standard 10-K filing header and does not contain specific financial performance details or forward-looking statements that would indicate a high-risk profile.

Key Numbers

• 20240430 — Fiscal Year End (Reporting period for the 10-K)
• 20240719 — Filing Date (Date the 10-K was submitted to the SEC)

Key Players & Entities

• CHAMPIONS ONCOLOGY, INC. (company) — Filer
• CHAMPIONS BIOTECHNOLOGY, INC. (company) — Former company name
• 855 N. WOLFE STREET SUITE 619 BALTIMORE, MD 21205 (address) — Business and Mail Address
• 0000771856 (company_id) — Central Index Key

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share CSBR The Nasdaq Stock Market
• $125,000 — evaluation. Typical studies are in the $125,000 price range, with an increasing number
• $250,000 — an increasing number of studies in the $250,000 to $500,000 range. Studies performed in
• $500,000 — ng number of studies in the $250,000 to $500,000 range. Studies performed in a regulator
• $50.1 m — ucts and services totaled approximately $50.1 million, a decrease of approximately 7% f
• $223 billion — ug market is estimated to be as high as $223 billion in 2023. Competition in this industry i
• $9.5 million — , 2024 and 2023, we spent approximately $9.5 million and $11.5 million, respectively, to fur
• $11.5 m — we spent approximately $9.5 million and $11.5 million, respectively, to further develop

Filing Documents

• csbr-20240430.htm (10-K) — 1071KB
• csbrex414302024.htm (EX-4.1) — 3KB
• csbrex214302024.htm (EX-21) — 3KB
• csbrex2314302024.htm (EX-23.1) — 3KB
• csbrex3114302024.htm (EX-31.1) — 11KB
• csbrex3124302024.htm (EX-31.2) — 11KB
• csbrex3214302024.htm (EX-32.1) — 8KB
• csbrex974302024.htm (EX-97) — 23KB
• 0001628280-24-032321.txt ( ) — 6178KB
• csbr-20240430.xsd (EX-101.SCH) — 43KB
• csbr-20240430_cal.xml (EX-101.CAL) — 72KB
• csbr-20240430_def.xml (EX-101.DEF) — 161KB
• csbr-20240430_lab.xml (EX-101.LAB) — 610KB
• csbr-20240430_pre.xml (EX-101.PRE) — 396KB
• csbr-20240430_htm.xml (XML) — 793KB

Risk Factors

Item 1A. Risk Factors 6

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 14

Cybersecurity

Item 1C. Cybersecurity 14

Properties

Item 2. Properties 14

Legal Proceedings

Item 3. Legal Proceedings 15

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 15 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 15

Reserved

Item 6. Reserved 16

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 22

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 22

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 22

Controls and Procedures

Item 9A. Controls and Procedures 22

Other Information

Item 9B. Other Information 23

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 23 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 23

Executive Compensation

Item 11. Executive Compensation 23

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 24

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 24

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 24 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules. 24

Form 10-K Summary

Item 16. Form 10-K Summary 26 Signatures 27 1 As used in this Annual Report on Form 10-K (this "Annual Report"), "Champions Oncology, Inc.," "Champions," the "Company," "we," "ours," and "us" refer to Champions Oncology, Inc. and its subsidiaries, except where the context otherwise requires or as otherwise indicated. DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") that inherently involve risk and uncertainties. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "likely" or similar expressions. Forward-looking statements in this Annual Report include statements about our business strategies and products development activities, including the anticipated benefits and risks associated with those strategies as well as statements about the sufficiency of our capital resources. One should not place undue reliance on these forward-looking statements. We cannot guarantee that we will achieve the plans, intentions or expectations expressed or implied in our forward-looking statement. There are a number of important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied in the forward-looking statements we make. These important factors are described under "Risk Factors" set forth below. In addition, any forward-looking statements we make in this Annual Report speak only as of the date of this document, and we do not intend to update any such forward-looking statements to reflect events or circumstances that occur after that date, except as required by law. As a result of these and other factors, our stock price may fluctuate dramatically. PAR

Business

Item 1. Business Overview We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed. The PDX bank is highly characterized at the molecular, phenotypic and pharmacological levels, which provides a differentiated layer of data for our large oncology dataset (the "Datacenter"). The Datacenter combines our proprietary dataset with other large publicly available datasets. This dataset currently includes approximately 3,500 molecular datasets (genomics, transcriptomics, proteomics, phosphor-proteomics), approximately 3,000 clinical drug responses, approximately 3,500 in vivo drug responses, and the accompanying clinical information on the patients from which they were derived (pre and post tumor sample acquisition of drug treatments and responses, age, ge

Risk Factors

Item 1A. Risk Factors You should carefully consider the risks described below together with all of the other information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known, or those we currently consider insignificant, may also impair our business operations in the future. We historically incurred losses from operating activities, may require significant capital and may never

View Full Filing

View this 10-K filing on SEC EDGAR